Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin

Inclusion Criteria: 1. Patients with newly histologically confirmed nasopharyngeal carcinoma, including WHO III 2. Newly diagnosed T3-4 or any TN2-3 locally advanced nasopharyngeal carcinoma 3. At least one measurable lesion (according to the RECIST1.1) 4. female and male,18-70 years of age 5. ECOG performance status of 0-1 6. Life expectancy of more than 3 months 7. Without radiotherapy or chemotherapy 8. Adequate organ function including the following: Platelets count \>= 100 \* 109/l Absolute neutrophil count (ANC) \>= 2.0 \* 109/l Hemoglobin \>= 90 g/l Total bilirubin \<= 1.5ULN AST and ALT \<= 2.5ULN,if there is liver metastasis , AST and ALT \<= 5ULN Serum creatine \<= 1.5ULN 9. Signed and dated informed consent. Exclusion Criteria: 1. Before or at the same time any second malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix 2. Evidence of distant metastasis 3. Taboos of chemotherapy or radiotherapy(such as heart failure, angina pectoris, or cardiac arrhythmia.et al) Presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia 4. Pregnant or breast-feeding females 5. Abuse of psychiatric drugs or dysphrenia 6. Prior chemotherapy with raltitrexed or cisplatin 7. Allergic to clinical drugs 8. Participation in clinical trials for other anti-tumor drugs in 4 weeks 9. Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study